SLP simulations-plus.com Net Financial Result

Corporate emblem and logo of Simulations Plus (SLP)

The visualization of Simulations Plus, Inc. (SLP) financial quotes on the GURU.Markets platform demonstrates profit dynamics, which currently stand at 0.01. Simulations Plus, Inc. (SLP) develops biosimulation software that enables pharma behemoths to radically reduce testing costs. Such digital tests minimize the use of reagents, supporting environmental standards. The high value of the product provides the business with powerful leverage for flexible pricing power over its licenses.

SLP Simulations Plus, Inc. Company Net Income (07/04/2022 - 10/18/2026)

Analytical breakdowns and data insights for company Simulations Plus (SLP)

- stock quotes and analyst forecast:
Share Price Simulations Plus Inc.|SLP - Price Target Chart
- market capitalization data:
Market Capitalization Simulations Plus Inc.|SLP - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Simulations Plus|SLP - Company Book Value|Market Cap to Net Assets Ratio simulations-plus.com|SLP - Cumulative Company Assets
- debt burden and liquidity indicators:
Total Debt to Capital Simulations Plus, Inc.|SLP - Long-Term Debt to Equity|Short-Term Debt to Equity Simulations Plus Inc|SLP - Company Aggregate Debts|Debts to Book Capitalization Simulations Plus Inc.|SLP - Company Long-Term Liabilities|Amount of Current Liabilities Simulations Plus|Interim Coverage Ratio simulations-plus.com
- earnings and multiples data:
SLP - Company Net Income
Fundamental valuation:Simulations Plus, Inc.
Manufactured product of Simulations Plus Inc

Simulations Plus, Inc. (SLP) occupies a strategic niche as an IT partner for government regulators and pharmaceutical behemoths in the field of drug modeling. By analyzing the company's net profitability, an investor sees the real cash flow stripped of market volatility. This indicator captures the actual volume of funds generated by the business on a daily basis. Steady growth in this metric confirms the effective implementation of drug safety forecasting systems. Peak values here serve as a signal of either fundamental dominance or an imminent correction.

Key competitors

Company Profit VEEV|Company Net Income Doximity, Inc.|healthequity.com (HQY) - Net Financial Result|Net Profit WAY|Net Financial Result CorVel Corp|Company Net Income Privia Health Corp PRVA|HURN - Net Income|CERT: Net Income|OMCL - Net Profit|GoodRx (GDRX) - Company Net Income|SDGR (Schrodinger Inc) - Company Net Income|PHR (Phreesia Corp) - Net Profit|Net Profit Omada|Net Income EVH (Evolent Health, Inc.)|Profit After Payment of Taxes HSTM|Net Profit DH (Definitive Healthcare Corp.)|Net Financial Result Consensus Cloud Solutions Inc (CCSI)|AGL - Company Net Income|Company Net Income Absci Bio|So-Young International (SY) - Company Net Income|Company Profit NRC|Company Net Income Spok|OptimizeRx Corp (OPRX) - Net Financial Result|Net Income TBRG (CPSI)|SOPH (sophiagenetics.com) - Final Profit|Company Net Income Health Catalyst, Inc. HCAT|CCLD (CareCloud Inc.) - Profit After Tax|RSSS - Company Net Income|DLHC: Company Net Income|ONMD (onemednet.com) - Net Income|Scienture Corp (SCNX) - Net Profit|Company Net Income Healthcare Triangle|iSpecimen Corp (ISPC) - Net Financial Result|Net Income BFRG (Bullfrog AI Holdings)|WORX (SCWorx Corp) - Final Profit|Net Profit MSPR (LifeWallet)|Net Financial Result iCoreConnect, Inc. (ICCT)|MEDS - Company Net Income|ORGS (orgenesis.com) - Company Profit|RCM: Net Profit|Net Income Sharecare Inc.|Net Income STRM|Syra Health, Corp. (SYRA) - Net Financial Result|Company Net Income Apollo Medical Holdings (AMEH)|Net Financial Result modeln.com|Company Net Income NextGen Healthcare, Inc. NXGN